ERBB2 and neoplasm: Based on an extensive literature research we selected EpCAM, EGFR, HER2, and MUC1 to complement the immune-fluorescent detection of CTCs based on cytokeratins alone in protocol A. To find out whether these markers were indeed appropriate to detect CTCs in our cohort, we evaluated the microarray gene expression data from the respective primary tumor tissues.